Monday, April 20, 2009
MONDAY, April 20 (HealthDay News) -- Cutting-edge research is rapidly moving from bench to bedside in a variety of cancers, according to four studies highlighted this week at a press conference presented at the 100th Annual Meeting of the American Association for Cancer Research held from April 18 to 22 in Denver.
In one study, Jenilyn J. Virrey, from the University of Southern California in Los Angeles, and colleagues isolated endothelial cells from human nonmalignant brain and glioma tissues and studied the effects of 2,5-dimethyl-celecoxib. They found that the drug suppressed endothelial cell proliferation and migration.
In the three other studies, researchers reported on a method to manipulate T cells in the treatment of prostate cancer; the potential of combined inhibition of histone deacetylase and mammalian target of rapamycin in the treatment of pancreatic cancer; and the use of small molecule inhibitors to target PI3K and MEK proteins in general cancers.
"The most important challenge will be implementation," press conference host Pasi A. Janne, M.D., of the Harvard Medical School in Boston, said in a statement. "How can we determine the patients who are most likely to benefit from these new interventions? And along with implementation, how can we make sure that access is as widespread as possible? We do not want the best therapies to only be available at the top hospitals."
Genentech sponsored one of the studies, and several authors have financial ties to the company.
Diabetes & Endocrinology
Copyright © 2009 ScoutNews, LLC. All rights reserved.